Vicarious Surgical (NYSE:RBOT – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.
A number of other brokerages also recently issued reports on RBOT. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vicarious Surgical in a report on Wednesday, January 21st. BTIG Research reissued a “neutral” rating on shares of Vicarious Surgical in a report on Friday, December 12th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $7.00.
Read Our Latest Stock Analysis on RBOT
Vicarious Surgical Stock Performance
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of RBOT. Armistice Capital LLC bought a new stake in Vicarious Surgical in the fourth quarter worth $1,314,000. Jane Street Group LLC bought a new position in Vicarious Surgical during the fourth quarter valued at $98,000. Connective Capital Management LLC bought a new position in Vicarious Surgical during the third quarter valued at $169,000. XTX Topco Ltd purchased a new position in shares of Vicarious Surgical in the 4th quarter worth $27,000. Finally, Geode Capital Management LLC grew its stake in shares of Vicarious Surgical by 26.0% in the 4th quarter. Geode Capital Management LLC now owns 40,494 shares of the company’s stock worth $88,000 after buying an additional 8,344 shares in the last quarter. 47.27% of the stock is owned by hedge funds and other institutional investors.
About Vicarious Surgical
Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.
The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.
Read More
- Five stocks we like better than Vicarious Surgical
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Vicarious Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicarious Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
